LCG
TVTX icon

Lisanti Capital Growth’s Travere Therapeutics TVTX Stock Holding History

Lisanti Capital Growth’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.43M Sell
48,185
-90,297
-65% -$2.7M 0.36% 90
2025
Q4 		$5.29M Buy
138,482
+8,970
+7% +$292K 1.25% 28
2025
Q3 		$3.1M Buy
+129,512
New +$2.43M 0.76% 64

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Lisanti Capital Growth's TVTX Position: Q1 2026 in Review

Lisanti Capital Growth reduced its Travere Therapeutics (TVTX) stake by 65% in Q1 2026, selling an estimated $2.7M and leaving 48,185 shares worth $1.43M. The position accounts for 0.36% of the portfolio, ranked #90.

Lisanti Capital Growth first reported a position in TVTX in Q3 2025 and has held it in 3 quarters since. The position peaked at $5.29M in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Lisanti Capital Growth held 48,185 shares of Travere Therapeutics worth $1.43M as of Q1 2026.
  • Lisanti Capital Growth sold 90,297 Travere Therapeutics shares in Q1 2026, an estimated $2.7M.
  • Travere Therapeutics made up 0.36% of Lisanti Capital Growth's portfolio in Q1 2026, its #90 holding.
  • Lisanti Capital Growth first reported a position in Travere Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Lisanti Capital Growth's Travere Therapeutics position peaked at $5.29M in Q4 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Lisanti Capital Growth's 13F filing for Q1 2026, filed 7 May 2026.